St. Jude Medical to Present Data from 16 Research Abstracts and Highlight Its Product Portfolio at the 2014 North American Neuromodulation Society Meeting

ST. PAUL, Minn.--(BUSINESS WIRE)--

St. Jude Medical, Inc. STJ, a global medical device company, will present data from 16 clinical research programs at the upcoming North American Neuromodulation Society (NANS) meeting in Las Vegas, Nevada, December 11 – 14, 2014.

The data will be presented in oral and poster form, and will span the breadth of St. Jude Medical's chronic pain portfolio. Products presented in the St. Jude Medical booth and at the company's Innovation Suite – both located at booth 415 – will include the Protégé™ upgradeable implantable pulse generator (IPG), Penta™ five column paddle leads and Burst™ novel waveform therapy (not available in the US).

St. Jude Medical highlights at NANS 2014 will include:

• Upgradeable technology

The Protégé IPG is the industry's first system to allow patients to upgrade their device via software updates, allowing access to future therapies when approved without surgical IPG replacement.

• Examining the safety and efficacy of 5-column Penta™ paddle leads

The St. Jude Medical Penta lead has been shown to provide broad stimulation across the spinal cord both within and outside the anatomical midline addressed by traditional leads. New research at NANS will evaluate the safety of the Penta lead and the product's ability to efficiently generate clinically meaningful pain relief, improved quality of life and treatment satisfaction.

Session: Safety and Efficacy of 5-Column Penta Paddle Leads for Spinal Cord Stimulation (12/12/14; 5:15 PM)

• Assessing the importance of therapeutic tuning of the SCS therapy to patients pain condition

New research presented at NANS 2014 will examine the effects of Burst™ stimulation waveform therapy on reducing pain levels in patients who don't respond to traditional tonic stimulation. Research will also assess the impact of tailoring lead type, number and target on patient outcomes. (Caution: Investigational Device. Limited by Federal Law to investigational use.)

Sessions: Patients Reporting Moderate-Severe Pain using Tonic Spinal Cord Stimulation Reported Mild-Moderate Pain Using Burst Stimulation (12/12/14; 5:15 PM) & Impact of Tailoring Spinal Cord Stimulation Therapy on Clinical Outcomes (12/12/14; 5:15 PM)

• SCS therapy's role in reducing opioid usage and decreasing health care utilization

In two separate data presentations presented at NANS, researchers will evaluate the ability of SCS therapy to affect opioid usage in patients and whether considering SCS earlier in the chronic pain care continuum may reduce patient health care utilization and overall probability of success with the therapy.

Sessions: Associations of Opioid Usage and SCS Efficacy: Results form a Large Post Market Study (12/11/14; 5:30 PM) & Patient Healthcare Utilization is Higher with Longer Delays from Pain Diagnosis to Spinal Cord Stimulation (12/14/14; 5:15 PM)

Additional St. Jude Medical research presented throughout NANS 2014 will explore predictors of patient success and response to therapy, the influence of time and prior treatments on pain scores in SCS patients and whether a definitive “atlas” could help map associations between electrode location and patient parathesia.

For a full list of St. Jude Medical research abstracts scheduled to be presented at NANS 2014, click here.

About the St. Jude Medical Chronic Pain Portfolio

Chronic pain affects approximately 1.5 billion people worldwide, more than heart disease, cancer and diabetes combined. The condition can negatively impact personal relationships, work productivity and a patient's daily routine, and costs the U.S. health system up to $300 billion annually, including nearly 515 million workdays lost and 40 million doctor visits each year. St. Jude Medical offers multiple solutions for patients to manage debilitating chronic pain, including spinal cord stimulation (SCS) and radiofrequency ablation.

About St. Jude Medical

St. Jude Medical is a global medical device manufacturer dedicated to transforming the treatment of some of the world's most expensive epidemic diseases. The company does this by developing cost-effective medical technologies that save and improve lives of patients around the world. Headquartered in St. Paul, Minn., St. Jude Medical has four major clinical focus areas that include cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit sjm.com or follow us on Twitter @SJM_Media.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company's control and the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2013 and Quarterly Report on Form 10-Q for the fiscal quarter ended September 27, 2014. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.